Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials-Reference-Cited by-同舟云学术

Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials

Published:2020-05-14 Issue:1 Volume:20 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Nie Run-Cong,Zou Xue-Bin,Yuan Shu-Qiang,Chen Ying-Bo,Chen Shi,Chen Yong-Ming,Chen Guo-Ming,Chen Xiao-Jiang,Luo Tian-Qi,Li Shu-Man,Duan Jin-Ling,Wang Yun,Li Yuan-Fang

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-020-06910-5.pdf

Reference42 articles.

1. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371:1039–49.

2. Malvezzi M, Bertuccio P, Levi F, et al. European cancer mortality predictions for the year 2014. Ann Oncol. 2014;25:1650–6.

3. Sinn M, Bahra M, Denecke T, et al. Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival. World J Gastrointest Oncol. 2016;8:248–57.

4. Heestand GM, Murphy JD, Lowy AM. Approach to patients with pancreatic cancer without detectable metastases. J Clin Oncol. 2015;33:1770–8.

5. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120:899–903.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward;eClinicalMedicine;2024-09

2. Growth Hormone Receptor Antagonist Markedly Improves Gemcitabine Response in a Mouse Xenograft Model of Human Pancreatic Cancer;International Journal of Molecular Sciences;2024-07-06

3. Surrogacy of Recurrence-free Survival for Overall Survival as an Endpoint of Clinical Trials of Perioperative Adjuvant Therapy in Hepatobiliary-pancreatic Cancers;Annals of Surgery;2023-08-28

4. Evaluating relapse-free survival as an endpoint for overall survival in adjuvant immunotherapy trials;JNCI: Journal of the National Cancer Institute;2023-06-30

5. Post‐operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression;The Journal of Pathology: Clinical Research;2023-06-08